Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy
Immune checkpoint inhibition (ICI) shows potential for cancer therapies, but response rates vary. Here, the authors use single-cell analyses to show that, in a 28 patient cohort, patients stratified by mucosal-associated invariant T (MAIT) percentages show different response rates, and ICI responder...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2021-03-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-021-21928-4 |
| _version_ | 1818977525797224448 |
|---|---|
| author | Sara De Biasi Lara Gibellini Domenico Lo Tartaro Simone Puccio Claudio Rabacchi Emilia M. C. Mazza Jolanda Brummelman Brandon Williams Kelly Kaihara Mattia Forcato Silvio Bicciato Marcello Pinti Roberta Depenni Roberto Sabbatini Caterina Longo Massimo Dominici Giovanni Pellacani Enrico Lugli Andrea Cossarizza |
| author_facet | Sara De Biasi Lara Gibellini Domenico Lo Tartaro Simone Puccio Claudio Rabacchi Emilia M. C. Mazza Jolanda Brummelman Brandon Williams Kelly Kaihara Mattia Forcato Silvio Bicciato Marcello Pinti Roberta Depenni Roberto Sabbatini Caterina Longo Massimo Dominici Giovanni Pellacani Enrico Lugli Andrea Cossarizza |
| author_sort | Sara De Biasi |
| collection | DOAJ |
| description | Immune checkpoint inhibition (ICI) shows potential for cancer therapies, but response rates vary. Here, the authors use single-cell analyses to show that, in a 28 patient cohort, patients stratified by mucosal-associated invariant T (MAIT) percentages show different response rates, and ICI responders have more MAIT cells expressing CXCR4 and granzyme B. |
| first_indexed | 2024-12-20T16:29:08Z |
| format | Article |
| id | doaj.art-5dde8cd7955f4749b3113f29084ac913 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-12-20T16:29:08Z |
| publishDate | 2021-03-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-5dde8cd7955f4749b3113f29084ac9132022-12-21T19:33:17ZengNature PortfolioNature Communications2041-17232021-03-0112111110.1038/s41467-021-21928-4Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapySara De Biasi0Lara Gibellini1Domenico Lo Tartaro2Simone Puccio3Claudio Rabacchi4Emilia M. C. Mazza5Jolanda Brummelman6Brandon Williams7Kelly Kaihara8Mattia Forcato9Silvio Bicciato10Marcello Pinti11Roberta Depenni12Roberto Sabbatini13Caterina Longo14Massimo Dominici15Giovanni Pellacani16Enrico Lugli17Andrea Cossarizza18Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio EmiliaDepartment of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio EmiliaDepartment of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio EmiliaLaboratory of Translational Immunology, IRCCS Humanitas Research HospitalDepartment of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio EmiliaLaboratory of Translational Immunology, IRCCS Humanitas Research HospitalLaboratory of Translational Immunology, IRCCS Humanitas Research HospitalBio-Rad LaboratoriesBio-Rad LaboratoriesDepartment of Life Sciences, University of Modena and Reggio EmiliaDepartment of Life Sciences, University of Modena and Reggio EmiliaDepartment of Life Sciences, University of Modena and Reggio EmiliaDepartment of Oncology, University of Modena & Reggio EmiliaDepartment of Oncology, University of Modena & Reggio EmiliaDepartment of Surgery, Medicine, Dentistry and Morphological Sciences, University of Modena and Reggio EmiliaDepartment of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio EmiliaDepartment of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio EmiliaLaboratory of Translational Immunology, IRCCS Humanitas Research HospitalDepartment of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio EmiliaImmune checkpoint inhibition (ICI) shows potential for cancer therapies, but response rates vary. Here, the authors use single-cell analyses to show that, in a 28 patient cohort, patients stratified by mucosal-associated invariant T (MAIT) percentages show different response rates, and ICI responders have more MAIT cells expressing CXCR4 and granzyme B.https://doi.org/10.1038/s41467-021-21928-4 |
| spellingShingle | Sara De Biasi Lara Gibellini Domenico Lo Tartaro Simone Puccio Claudio Rabacchi Emilia M. C. Mazza Jolanda Brummelman Brandon Williams Kelly Kaihara Mattia Forcato Silvio Bicciato Marcello Pinti Roberta Depenni Roberto Sabbatini Caterina Longo Massimo Dominici Giovanni Pellacani Enrico Lugli Andrea Cossarizza Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy Nature Communications |
| title | Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy |
| title_full | Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy |
| title_fullStr | Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy |
| title_full_unstemmed | Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy |
| title_short | Circulating mucosal-associated invariant T cells identify patients responding to anti-PD-1 therapy |
| title_sort | circulating mucosal associated invariant t cells identify patients responding to anti pd 1 therapy |
| url | https://doi.org/10.1038/s41467-021-21928-4 |
| work_keys_str_mv | AT saradebiasi circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT laragibellini circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT domenicolotartaro circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT simonepuccio circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT claudiorabacchi circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT emiliamcmazza circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT jolandabrummelman circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT brandonwilliams circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT kellykaihara circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT mattiaforcato circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT silviobicciato circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT marcellopinti circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT robertadepenni circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT robertosabbatini circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT caterinalongo circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT massimodominici circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT giovannipellacani circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT enricolugli circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy AT andreacossarizza circulatingmucosalassociatedinvarianttcellsidentifypatientsrespondingtoantipd1therapy |